

# IAVI at the 7<sup>th</sup> Global forum on TB Vaccines

8-10 October, 2024 | Rio de Janeiro, Brazil

## Opening Session

### Opening remarks

*Mark Feinberg, President & CEO*

Tuesday, 8 October – 10:00-12:30

*Grande Sala*

---

## Plenary Sessions

### Plenary 1: From discovery to access

Clinical development of new TB vaccines: State of the Field

*Elana Van Brakel, Medical Director*

Tuesday, 8 October – 13:30-15:00

*Grande Sala*

### Plenary 4: Country scale-up and implementation of new TB vaccines

*Shelly Malhotra, Vice President, Global Affairs and Global Access*

Wednesday, 9 October – 14:00-15:30

*Grande Sala*

### Plenary 6: Enabling TB vaccine development through funding, political will, open science, and engaged communities

Clinical development of new TB vaccines: State of the Field

*Shaun Palmer, Communications & Advocacy Specialist; Co-Lead of the TB Vaccine Advocacy Roadmap (TB Vax ARM)*

Thursday, 10 October – 15:15-16:15

*Grande Sala*

---

## Oral Abstracts

### OA1: Mechanisms of biomarkers and protection, novel approaches, human challenge, optimizing animal models

Co-chair: *Lewis Schragger, TB Impact Area Senior Leader*

Wednesday, 9 October – 11:30-13:00

*Grande Sala*

### Effectiveness of primary Bacillus Calmette-Guérin against the risk Mycobacterium tuberculosis infection and tuberculosis disease: an individual-participant meta-analysis of trials and observational studies

(Session – OA2: Advancing clinical development)

*Puck Pelzer, Associate Director, Epidemiology*

Wednesday, 9 October – 11:30-13:00

*Teatro de Câmara*

### Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India

(Session – OA4: Impact, implementation, policy)

*Jessy Joseph, Senior Manager, Global Access Research*

Thursday, 10 October – 11:30-13:00

*Teatro de Câmara*

---



## Posters

- Accelerating TB vaccine development by “planning for success”: The MTBVAC phase 2b clinical trial to prevent TB in African adolescents and adults** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Lewis Schrager, TB Impact Area Senior Leader*
- Integrated clinical research center selection for phase 2b MTBVAC TB prevention efficacy trial in African adolescents and adults** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Puck Pelzer, Associate Director, Epidemiology*
- Evolution of Tuberculosis Vaccine Modelling studies: Insights from studies in India** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Ruchita Jalal, Senior Specialist, Clinical Operations & Epidemiology*
- Forecasting TB vaccine demand to support supply and procurement planning** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Jessy Joseph, Senior Manager, Global Access Research*
- The TB Vaccine Advocacy Roadmap (TB Vax ARM): A global case study of advocacy best practice** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Shaun Palmer, Communications & Advocacy Specialist; Co-Lead of the TB Vaccine Advocacy Roadmap (TB Vax ARM)*
- Financing and policy innovation to advance TB vaccines through licensure: A G20 policy proposal** Tuesday, 8 October – 15:00-16:30  
*Poster Viewing, Grande Sala Foyer*  
*Shaun Palmer*
- 

## Discussion Session

- From political commitments to action to deliver new TB vaccines this decade: A TB Vax ARM discussion session** Thursday, 10 October – 14:00-15:00  
*Room to be announced*  
*Co-chair: Shaun Palmer*
- 

## Community Declaration

IAVI is proud to lead the Forum’s first-ever Community Engagement Committee. On behalf of the committee, supporters are invited to sign the official Community Declaration. Developed in consultation with the global TB community, the declaration outlines the demands of TB affected communities for the development and implementation of new TB vaccines.

### Deadline

- 2pm BRT
- Thursday, 10 October 2024

[Sign the declaration](#)

---

